Project Grant R61AI187113
Award Date
12/20/24
Completion Date
11/30/27
Dollars Obligated
$345K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Cincinnati, OH 45221, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $402,860 to the University of Cincinnati to develop a molecular toolbox for the fungal pathogen Pneumocystis jirovecii (PJ). The primary goal is to establish a transformation system for this non-culturable organism using CRISPR/Cas9 gene editing and plasmid-mediated approaches. During the initial R61 phase, the project...
This $170,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research by Prokaryotics Incorporated to develop novel antifungal therapeutics. The key objectives are to conduct structural biology studies on the fungal enzyme MCD4, which is involved in glycosylphosphatidylinositol (GPI) biosynthesis, and to leverage these insights to synthesize and evaluate new antifungal...
This Project Grant award of $558,747, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate a novel link between the fungal virulence factor calcineurin, amino acid permease, and protein kinase A in the pathogen Mucor that causes the life-threatening infection mucormycosis. The research aims to identify key transcription factors regulated by calcineurin, elucidate the...
This federal Project Grant award for $857,215 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to investigate how the fungal pathogen Candida albicans adapts and causes infection in different host environments, specifically the oral/mucosal and systemic/invasive infection niches. The research aims to decipher how the fungal GCN5 acetylation system confers...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $406,450.00 to support research on the continuous in vitro culture and genetics of the Plasmodium vivax malaria parasite. The key objectives are to: 1) optimize the production of reticulocytes (young red blood cells) to support continuous P. vivax culture, 2) optimize culture conditions using a bespoke...
This federal Project Grant award of $2,366,783 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will fund research to determine the molecular processes by which infectious Cryptococcus spores transition into vegetatively growing yeast (germinate) and how this process influences disease progression. The research, conducted by the University of Wisconsin-Madison, aims to gain a better understanding of...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $147,656 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to St. Jude Children's Research Hospital Inc. The award supports research to investigate how mucin, a key component of mucus, inhibits the autolysis (self-destruction) of the pathogenic bacterium Streptococcus pneumoniae. The research aims to determine the specificity and impact of this mucin-mediated autolysis inhibition on...
This federal Project Grant award of $787,043 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to elucidate the evolutionary history of symbiotic associations between the Mucoromycotina fungi and their endosymbiotic bacteria. The primary objectives are to gain insights into population-level processes that govern these fungal-bacterial symbioses, including the role of epigenetic reprogramming via...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $750,815 in funding to the University of Maryland, Baltimore to support research into therapeutic targeting of the host hypoxia-response pathway to treat mucormycosis, a deadly invasive fungal infection. The key objectives of this 5-year research project are to examine the role of the protein ANGPTL4 in the...
This federal Project Grant award for $392,710, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), is focused on establishing continuous, high-yield culture systems for the malaria parasite Plasmodium vivax (P. vivax). The key objectives are to: 1) develop robust P. vivax cultures that can invade multiple reticulocyte subsets, and 2) use this culture system to test triggers of gametocytogenesis...